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Abstract
Angiotensin-converting enzyme (ACE) generates the vaso­
constrictor angiotensin II, which plays a critical role in 
maintenance of blood pressure in mammals. Although sig­
nificant ACE activity is found in plasma, the majority of the 
enzyme is bound to tissues such as the vascular endothe­
lium. We used targeted homologous recombination to create 
mice expressing a form of ACE that lacks the COOH-termi- 
nal half of the molecule. This modified ACE protein is cata- 
lytically active but entirely secreted from cells. Mice that ex­
press only this modified ACE have significant plasma ACE 
activity but no tissue-bound enzyme. These animals have 
low blood pressure, renal vascular thickening, and a urine 
concentrating defect. The phenotype is very similar to that 
of completely ACE-deficient mice previously reported, except 
that the renal pathology is less severe. These studies strongly 
support the concept that the tissue-bound ACE is essential 
to the control of blood pressure and the structure and func­
tion of the kidney. (J. Clin. Invest. 1997. 99:2375-2385.) Key 
words: peptidyl-dipeptidase A • blood pressure • kidney • 
urine concentration • male fertility
Introduction
Angiotensin-converting enzyme (ACE)1 plays a central role in 
the renin-angiotensin system through generation of the pep­
tide angiotensin II from its inactive precursor angiotensin I  (1). 
Angiotensin II  induces vasoconstriction, aldosterone release, 
and other physiologic actions that act to raise blood pressure 
(2). A CE inhibitors block the formation of angiotensin II and 
have been used to treat hypertension and heart failure.
Cloning of A CE showed that this molecule is a single 
polypeptide chain that contains two homologous domains,
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each with an independent catalytic site (3-5). Each catalytic 
site is active against angiotensin I and other peptide substrates. 
While the two catalytic sites generate angiotensin II with equal 
efficiency, they vary in a number of biochemical parameters 
including the ability to hydrolyze peptide substrates other than 
angiotensin I (6). For example, the carboxy-terminal domain 
requires a higher chloride concentration for efficient hydroly­
sis of some substrates such as hippuryl-histidyl-leucine (HHL) 
and hippuryl-glycyl-glycine (HG G ). Furtherm ore, leutiniz- 
ing hormone-releasing hormone and the hematopoetic stem 
cell inhibiting peptide N -acetyl-seryl-aspartyl-lysyl-proline 
(AcSDKP) are cleaved more efficiently by the amino terminal 
catalytic site than by the carboxyl-terminal active site (7, 8). 
Although the amino-terminal domain does cleave AcSDKP in 
vivo (9), the physiological significance of the two catalytic sites 
is not at present known.
The vast majority of A CE enzymatic activity is associated 
with tissues such as the vascular endothelium and the proximal 
tubular epithelium of the kidney. A CE is an ectoenzyme; both 
catalytic domains are found outside of cells, while the protein 
is bound to cell membranes by a hydrophobic anchor sequence 
found at the carboxyl terminus (1). A CE activity is also found 
in a soluble form  within plasma resulting from  the enzymatic 
cleavage of tissue-bound A CE (10). The functional signifi­
cance of circulating A CE versus tissue-bound A CE has been 
of great interest since 1967 when Ng and Vane first em pha­
sized the physiologic role of lung A CE activity in the conver­
sion of angiotensin I to angiotensin II (11). Others have failed 
to correlate the antihypertensive effects of A CE inhibitors 
with the degree of plasma A CE inhibition (12). These data 
support the hypothesis that tissue-bound A CE activity plays a 
major role in the production of angiotensin II. Furtherm ore, 
such studies suggest that tissue-bound A CE may participate in 
local renin-angiotensin systems that function independently 
from  the circulating renin-angiotensin system (13).
A  unique form of A CE is found in the testis. This isozyme 
is called testis A CE, and it is transcribed in postmeiotic male 
germ cells using a unique testis-specific prom oter located 
within the 12th intron of the somatic A C E  gene (14, 15). Testis 
A C E is about half the size of somatic A CE and contains only 
the carboxyl-terminal catalytic domain. R ecent studies of 
ACE-deficient mice have suggested that testis A CE plays an 
im portant role in male fertility (16, 17).
Previous studies of A CE deficient mice by Krege et al. (16) 
and our lab (17) were unable to distinguish between the effects 
of somatic A CE and testis A C E since the animals lacked both 
isozymes. To address this issue, we attem pted to create a 
mouse strain expressing only the somatic form of ACE. We 
succeeded in generating mice that lack testis A CE and have a 
partial restoration of plasma somatic ACE. However, the so­
matic A CE in these animals is truncated and contains only the 
amino-terminal active site. M ore importantly, this form  of
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A CE lacks the membrane-spanning anchor region and is 
therefore found only as a soluble enzyme. Although this solu­
ble enzyme can generate angiotensin II efficiently, these ani­
mals (now term ed ACE.2) have very low blood pressure, renal 
vascular thickening, an inability to concentrate urine, and re­
duced male fertility. This phenotype is very similar to that of 
our ACE.1 mice, which completely lack all A C E (17). This 
similarity between ACE.1 and ACE.2 mice supports the hy­
pothesis that tissue-bound A CE is critically im portant in the 
physiologic generation of angiotensin II.
Methods
Creation o f  mice with a mutant A C E  allele
The DNA construct used for targeted homologous recombination 
was a modification of a previously described targeting construct (17). 
The previous construct consisted of two arms of ACE  genomic DNA 
flanking a 3.1-kb neomycin cassette. One arm contained 6.9 kb of 
ACE  genomic sequence extending from the middle of somatic ACE  
exon 1 to 91 bp 5' of the testis ACE  transcription start site. The sec­
ond arm was 1.8 kb of genomic ACE  sequence extending from 17 bp 
downstream of the testis ACE  transcription start site to the middle of 
somatic ACE  exon 15. In this construct, the testis ACE  translation 
start site was changed from ATG to TTG. The resulting construct is 
missing the DNA sequence between —91 bp and +17 bp relative to 
the testis ACE  transcription start site. A 1.8-kb thymidine kinase cas­
sette was inserted 3' to the other fragments.
The targeting construct used for the ACE.2 mice differs from the 
previous construct in having a 2.2-kb fragment of ACE  cDNA in­
serted into MluI and EcoRV sites immediately 5' to the neomycin 
cassette. This cDNA fragment was generated by PCR from cloned 
ACE  cDNA with the primers 5'- CAGAACGCGTGCAGACCTA- 
GAGACTGATGAAGC-3' and 5'-CAGACGATATCGACCTT- 
TAATTGTATTCACAG-3'. The fragment incorporates 2.2 kb of 
ACE  cDNA sequence including all of the somatic ACE  coding exons 
(13-25) downstream of the neomycin cassette in the previous con­
struct and 216 bp of 3' untranslated region including a poly-adenyla- 
tion site. The cDNA fragment contains a consensus 3' splice acceptor 
sequence (GCAG) immediately 5' of the coding region.
The DNA construct was linearized with NotI and electroporated 
into R1 ES cells. The isolation of targeted homologous recombinants 
and the generation of chimeric heterozygotes and homozygous mice 
was performed as previously described (18). Genotyping was per­
formed by Southern blot and PCR analyses (17).
A C E  assays
Plasma was collected either by retroorbital bleed into heparinized 
capillary tubes or via heparinzed syringe from the inferior vena cava 
of animals anesthetized with metofane. Tissues were taken from 
anesthetized animals, frozen in liquid nitrogen, and stored at —80°C 
until needed. The tissues were then homogenized in ACE homogeni- 
zation buffer (50 mM Hepes, pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 
25 ^M ZnCl2, 1 mM PMSF) and clarified by centrifugation for 15 min 
at 10,000 g. ACE activity against the artificial substrate hippuryl-gly- 
cyl-glycine was determined using the ACE-DIRECT REA (ALPCO, 
Windham, NH). For this assay, plasma was diluted 1:4 and tissue di­
luted to 30 ^g protein per assay in reaction buffer. All samples were 
measured in duplicate.
Initial velocities of wild-type ACE (+/+) and homozygous mu­
tant ACE (—/—) were determined using HHL, AcSDKP and angio­
tensin I as substrate over a concentration range of 0.02 to 1.25 mM. 
Assays were performed in a pool of plasma of + /+ and —/— mice, di­
luted 1/50 and 1/25, respectively. In addition, angiotensin I to angio­
tensin II conversion was measured in individual plasma samples. The 
rate of hydrolysis of all substrates used was quantified by HPLC on a 
Waters apparatus consisting of 600 controllers (Waters Co., Milford,
MA), absorbance detectors 486 and 717 autosampler or 712 WISP di­
rected by a Millenium chromatography manager.
HHL. Assay was performed in 300 mM chloride as described by 
Cushman and Cheung (19) and the released Hip was quantified by 
HPLC as previously described (5). The optimal chloride concentration 
for substrate hydrolysis was determined as previously described (5).
AcSDKP. Reactions were performed in 100 mM Hepes, pH 7.0, 
50 mM NaCl, 10 ^M ZnSO4, and terminated by the addition of 0.1% 
trifluoracetic acid (final concentration). The rate of hydrolysis of 
AcSDKP was determined by measuring the production the terminal 
Lys-Pro, which was resolved and quantified under isocratic condi­
tions (water: acetonitrile [98:2], 0.1% TFA). Unhydrolyzed AcSDKP 
was eluted and quantified by increasing the concentration of acetoni- 
trile to 10%. The products were resolved by reverse-phase HPLC, on a 
5-^m Puresil C18 column (Waters Co.) at a flow rate of 1 ml/min. Re­
tention times of KP and AcSDKP were 4.7 and 13.2 min, respectively, 
at a detection limit of 0.2 nmol at 200 nm.
Angiotensin I. Reactions were performed in 50 mM Hepes pH
7.5, 50 mM NaCl, 10 ^M ZnSO4, and stopped by the addition of 2% 
H3PO4 (final concentration). Angiotensin II and angiotensin I were 
resolved and quantified by isocratic reverse-phase HPLC in 18% 
(vol/vol) acetonitrile, 86 mM triethylammonium phosphate, pH 3.0, 
at a flow rate of 1 ml/min on a 3-^m Hypersil C18 column (Merck 
EM Science, Gibbstown, NJ) at 45°C. Retention times of angiotensin
II and angiotensin I were 3.4 and 7.0 min, respectively, at a detection 
limit of 0.5 nmol at 200 nm.
Northern blot
Poly A + RNA was isolated from the lungs and kidneys of one wild 
type, one heterozygous, and one homozygous mutant mouse using 
guanidine isothiocyanate (20) and oligo dT cellulose from the mRNA 
purification kit by Pharmacia (Uppsala, Sweden). Aliquots of mRNA 
were separated on a formaldehyde agarose gel, transferred to nylon 
and ACE  mRNA detected with 32P-labeled probe made from full 
length ACE  cDNA (4).
cDNA was prepared using poly A+ RNA and the Timesaver, 
cDNA Synthesis kit from Pharmacia. A portion of ACE  cDNA be­
tween positions 1758 and 2531 was amplified from the total cDNA by 
PCR using primers ACE.36 (5' -AGGTGTTGCAGGCTGGCTG-3') 
and ACE.85 (5'-AGGTTGTCAGACTCGTA-3'). The resulting prod­
uct was cloned into the TA cloning vector from Invitrogen (San Di­
ego, CA) and sequenced with the Sequenase 2.0 kit (Amersham 
Corp., Arlington Heights, IL).
Western blot
Tissue samples for Western blot were homogenized in RIPA buffer 
(20 mM Tris pH 7.4, 2.5 mM EDTA, 1% Triton X-100, 10% glycerol, 
1% deoxycholic acid, 0.1% SDS, 1 mM PMSF, 10 ng/ml Aprotinin). 
20 mg of protein was run by SDS-PAGE on a 7.5% gel, and the sepa­
rated proteins transferred to PVDF or nitrocellulose membranes. 
The membranes were probed with a rabbit polyclonal anti-mouse 
ACE antibody, and developed with an enhanced chemiluminescence 
kit from Amersham Corp. (21).
Histology
All samples for histological analysis were preserved in Bouin’s fixa­
tive or 10% formalin for at least 3 d. They were then embedded in 
paraffin and prepared using standard methods.
Blood pressure
Systolic blood pressures of the mice were determined using an auto­
mated tail cuff system as described by Krege et al. (22). Training mea­
surements were taken for 7 d to acclimatize the animals to the ma­
chine, followed by 4 d of recorded measurements. On each day, three 
sets of 10 measurements were taken for each mouse and the first set 
discarded. To eliminate bias caused by struggling animals or other 
difficulties, each set of measurements was accepted only if the stan­
dard deviation of the set was less than or equal to 9 mmHg.
2376 Esther et al.
For metabolic studies, all animals were pair-fed for 3 d. Urine was 
collected from animals of the same age and gender for 24 h in a meta­
bolic cage without food or water. Mineral oil was placed in the urine 
collection chamber to minimize evaporation. Water was removed for 
a total of 30 h including 6 h before the animals were placed in the 
metabolic cage. After 24 h, urine was collected, spun for 5 min at 
5,000 rpm to remove particulate matter and frozen at —20° until analysis.
Urine osmolality and electrolytes were determined by standard 
methods using the Wescat 5500 Vapor Pressure Osmometer (Wescor, 
Inc., Logan, UT).
Superovulation
Wild-type, female C57BL/6J mice were purchased from Harlan (Indi­
anapolis, IN) and superovulated when 5-6 wk old. Superovulation 
was induced by intraperitoneal injection of 5 U of pregnant mares se­
rum (gonadotrophin) between 1 and 3 p.m. followed by injection of 
5 U of human chorionic gonadotrophin 46 h later. Both hormones 
were purchased from Sigma Chemical Co. (St. Louis, MO). Super­
ovulated females were housed individually with single males begin­
ning the evening after the second injection. The following morning 
the males were removed, and the females checked for copulatory
Urine collection plugs. Females were killed during the last week of gestation, and the 
number of pups present in the uterus was counted.
Results
Creation o f  homozygous mutant mice. The genetic modifica­
tion of the A C E  locus was achieved using targeted homolo­
gous recombination in embryonic stem (ES) cells with the re ­
placement construct shown in Fig. 1 A. This construct was 
designed to replace a region extending from 91 bp upstream  of 
the testis A C E  transcription start site through the first 17 bp of 
the testis A C E  first exon with a neomycin cassette. Also, the 
testis A C E  transcription start site was changed from A TG to 
TTG. In a previously published study, we showed that these 
modifications eliminated testis A C E production in homozy­
gous m utant mice (17). We also found that these modifications 
of the testis A C E  prom oter region eliminated production of 
somatic ACE. To restore production of somatic A CE, a 
cDNA element containing all of the somatic A C E  coding re­
gions downstream of the neomycin cassette (exons 13 through
Figure 1. Targeted disruption of the ACE allele. (A) The top shows the wild-type ACE allele, with exons as filled boxes and the testis specific 
exon in gray. The somatic and testis ACE promoters are represented by arrows, and restriction sites are labeled below. The middle shows the 
targeting construct. This is composed of ACE genomic sequence from the middle of somatic ACE exon 1 to the middle of somatic ACE exon 15 
in which the testis ACE promoter has been deleted and replaced with a neomycin resistance cassette. A cDNA element encoding exons 13-25 of 
somatic ACE is inserted 5' to the neomycin resistance cassette. The construct was designed to eliminate testis ACE but allow for the production 
of somatic ACE despite the presence of the neomycin resistance cassette in the middle of the ACE gene. A thymidine kinase (TK) cassette at 
the 3' end of the construct allowed a positive/negative selection for homologous recombinants. The bottom shows the modified ACE allele after 
targeted homologous recombination. An additional EcoRV restriction site is present in the modified allele. (B) Southern blot analysis of ES 
cells. Genomic DNA was isolated from normal (+/+) and successfully targeted (+ /—) stem cells, digested with EcoRV, separated by agarose 
electrophoresis and blotted. The blot was probed with a 1-kb portion of cloned genomic DNA immediately 5' of somatic ACE exon 1 (17). The 
probe hybridizes to a > 20-kb fragment from the wild type allele and an 11.4-kb fragment from the modified allele.
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25) was inserted into intron 12 upstream of all other modifica­
tions. It was hoped that splicing of this cDNA into the somatic 
A C E  transcript would provide all of the genetic information 
needed to produce full length somatic ACE.
Construct D N A  was electroporated into R1 ES cells, and 
putative homologous recombinants were isolated by positive 
and negative selection. Proper homologous recombination was 
verified by Southern blot (Fig. 1 B ). ES cells containing the 
modified A C E  locus were injected into blastocysts of C57BL/6 
mice. Chimeric offspring were screened for incorporation of 
the modified allele by PC R  and mice bearing the modified al­
lele were bred to C57BL/6 females to produce the F1 genera­
tion. F1 animals were interbred to produce F2 generation mice 
that were either wild-type (+ /+ ), heterozygous (+ /—), or ho­
mozygous m utant (—/ —) for the A C E  locus. This strain of mice 
was designated ACE.2 to distinguish it from the ACE-defi­
cient ACE.1 strain animals previously characterized (17). Of 
the 202 F2 mice genotyped, 44 were wild-type, 121 were het­
erozygous, and 32 were homozygous mutant.
Genetic and biochemical analysis. Production of normal 
somatic A C E from the modified allele could occur only if the 
cDNA element is spliced correctly into the somatic A C E  tran­
script. To investigate splicing from the modified allele, m RNA 
was isolated from the lung and kidneys of wild-type, heterozy­
gous, and homozygous mutant mice. N orthern blot analysis for 
A C E  m RNA dem onstrated that the homozygous m utant mice 
produced small amounts of a transcript that appeared similar 
in size to the smaller of the two naturally occurring somatic 
A C E  transcripts (Fig. 2 A). The presence of a single transcript 
from the modified allele is expected since the construct con­
tains only one of the two polyadenylation sites that generate 
two transcripts in normal animals (4). To further examine
Figure 2. Northern blot and sequencing of modified ACE transcript. (A) Poly A+ RNA was isolated from the combined lung and kidneys of a 
wild-type (+/+), heterozygous (+ /—), and homozygous mutant (—/—) mouse. After electrophoresis, the poly A+ RNA was transferred to a ny­
lon membrane, and hybridized to a probe made from full-length ACE cDNA (4). More poly A+ RNA from the —/— mouse was loaded com­
pared to the other genotypes (4 vs. 2 ^g) to compensate for reduced signal. The wild type mouse contained the expected two ACE bands of 4.2 
and 4.9 kb. The heterozygous animal had reduced levels of the two bands, and the homozygous mutant had a low level of only the smaller of the 
two bands. (B) The top shows the predicted and actual splicing of the modified ACE gene between the naturally occurring exons (black boxes) 
and the cDNA element (white box). The resulting mRNA contains an extra 40 nt of sequence (gray box) between exons 1-12 and exons 13-24 
from the cDNA (middle). This encodes an in-frame stop codon just three amino acids downstream of exon 12. The normal protein structure of 
somatic ACE (bottom) consists of two homologous domains (ovals) with an NH2-terminal signal sequence (triangle) and a COOH-terminal hy­
drophobic membrane anchor (black bar). Because of the stop codon, the actual protein structure from the modified allele transcript consists of 
only the signal sequence and NH2-terminal domain.
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splicing, the region spanning the potential splice junction be­
tween exon 12 and the cDNA element was cloned by RT-PCR 
from  homozygous m utant mice. D N A  sequencing of the 
cloned fragment showed that the somatic transcript from the 
modified allele contained a 40 nucleotide insertion between 
exon 12 and the cDNA element (Fig. 2 B). This insertion re­
sulted from splicing to a cryptic splice acceptor site (tctct- 
cagTGGTCCTAG) located 40 bp upstream  of the cDNA ele­
ment within the twelfth intron. The insertion introduced an 
in-frame stop codon (TAG) just two amino acids after the last 
codon of exon 12. Therefore, although transcription from the 
modified allele produced a full-length m RNA, translation was 
predicted to term inate halfway through the transcript. To test 
this, blood from  wild-type, heterozygous, and homozygous 
m utant animals was collected, and plasma was analyzed by 
W estern blot with a polyclonal anti-ACE antibody (Fig. 3 A). 
A  single somatic A CE band was present in homozygous m u­
tant animals at a molecular mass of 85 kD. This size is roughly 
half that of normal somatic A CE from wild-type mice. H et­
erozygous mice contained both normal and modified forms of 
somatic ACE. These data are consistent with the predictions 
of the R N A  sequence analysis.
The truncation of A CE has two important consequences. 
First, the modified protein contains only the amino terminal 
domain of somatic ACE. Second, the modified protein lacks 
the carboxyl terminal hydrophobic tail that anchors somatic 
A C E to the plasma membrane of cells. Thus, the modified 
protein should be entirely secreted into plasma, resulting in lit­
tle or no tissue-bound A CE activity. Examination of lung, kid­
ney, and testis by W estern blot confirmed that no A CE protein 
was present in homozygous m utant animals (Fig. 3 B). The 
W estern blot also showed that the testis specific isoform of 
A C E is also absent in these mice.
To further examine the characteristics of the modified 
A C E protein, A C E enzyme activity was measured in plasma 
from  the three genotypes using the commercially available ar­
tificial substrate hippuryl-glycine-glycine (HGG). W ith this 
substrate, the homozygous m utant mice have about 15% the 
activity of wild-type animals (Fig. 4 A). Lung, kidney, and tes­
tis from these animals were also analyzed for A CE activity. 
Consistent with W estern blot analysis, no A CE activity was 
detected in any tissue from homozygous mutant mice (Fig. 4 B).
Interpretation of these results is complicated by the modi­
fied somatic A CE protein found in the homozygous mutant 
animals. The amino terminal domain of A CE differs from the 
carboxyl terminal domain in its affinity and catalytic activity 
towards various substrates. This is particularly true for the 
small substrates, as shown in Fig. 4 C. H ere, pooled plasma 
from each of the two genotypes was tested against substrates 
for which the individual catalytic activity of the two A CE do­
mains is known. The initial catalytic velocities were deter­
mined in zero order (substrate not limiting) conditions. AcSDKP 
is a naturally occurring amino-terminal specific substrate (8). 
This peptide was cleaved by plasma from homozygous mutant 
mice at rate 89%  of that of wild-type plasma. In contrast, the 
artificial substrate, H H L is almost exclusively an A CE car- 
boxy-terminal substrate in presence of high chloride concen­
tration (300 mM) (5). U nder these conditions, A CE activity in 
homozygous m utant plasma towards this substrate was only 
6%  of wild type, consistent with the results with H G G. The 
chloride sensitivity of A CE activity in plasma was also tested. 
The carboxy-terminal domain exhibits a large activation by
Figure 3. Western blot. (A) 20 ^g of protein from plasma of wild- 
type (+/+), heterozygous (+ /—), and homozygous mutant (—/—) 
mice were separated by SDS-PAGE, transferred to nitrocellulose, 
and were probed with rabbit polyclonal anti-ACE antibody. Normal 
soluble somatic ACE was detected in wild-type and heterozygous 
mice at 160 kD, but not in homozygous mutant mice. A modified 
85-kD form of ACE was found in heterozygous and homozygous mu­
tant mice, but not in wild type. (B ) Proteins from the lungs, kidneys, 
and testes of the three genotypes were analyzed by Western blot as 
previously described (17). Wild-type and heterozygous mice contain 
the normal 160-kD somatic ACE in lung and kidney and the 105-kD 
testis ACE isoform in the testis. Homozygous mutant mice do not 
contain any detectable ACE in any tissue. The modified 85 kD ACE 
protein was not detected in any genotype, even upon overexposure of 
the blot (data not shown).
chloride towards certain substrates, whereas the amino-termi­
nal domain is relatively chloride insensitive. This chloride acti­
vation is present in wild type plasma but abolished in homozy­
gous m utant plasma using either H H L (Fig. 4 D) or H G G  
(data not shown) as a substrate. These results confirm that the 
modified A CE allele produces a somatic A CE isoform that 
contains only the amino-terminal domain.
A CE activity assays with various substrates yield widely 
disparate measures of the enzyme activity in the blood of ho­
mozygous m utant mice. Although these values provide useful 
in vitro information, they are not directly relevant to the phys­
iologic role of A CE in vivo. The most physiologically appro­
priate measure of A CE activity is its ability to cleave angio­
tensin I to angiotensin II. W ith angiotensin I as a substrate, 
pooled plasma from  homozygous m utant mice have ^  34% 
the activity of wild-type plasma in initial velocity experiments 
(Fig. 4 C). Individual plasma samples were also analyzed for 
their ability to cleave angiotensin I under non-zero (substrate 
limiting) reaction conditions. The relative activity of homozy­
gous m utant mouse plasma was ^  75% of the activity of wild- 
type plasma (1.81±0.7 nmol angiotensin I/min per ml [—/ —] vs. 
2.34 + 1.71 nmol angiotensin I/min per ml [+ /+]). In these ex­
periments, ^  20% of the available angiotensin I was cleaved. 
These results dem onstrate that the modified A C E protein in 
homozygous m utant mice can generate a significant amount of 
angiotensin II.
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Figure 4. ACE activity assays. (A) Plasma was isolated from male and female wild-type (+/+, n = 7 males and 6 females), heterozygous (+ /—, 
n = 7 males and 6 females) and homozygous mutant (—/—, n = 7 males and 5 females) mice, diluted 1:4 and analyzed for ACE activity using the 
artificial substrate HGG. This assay reveals both gender and genotype differences, with homozygous mutant mice having ~  15% of the activity 
of wild-type mice. (B) Tissue from lung, kidney, and testis of male animals of the three genotypes (n = 4 +/+, 3 +/— and 3 —/—) were homoge­
nized in a detergent containing buffer and analyzed for ACE activity with HGG. ACE activity was reduced in heterozygotes and undetectable in 
all tissues from homozygous mutant mice. (C) The plasma ACE activity of wild-type and homozygous mutant mice was tested against three sub­
strates known to have different affinities for the NH2-terminal and COOH-terminal domains of normal somatic ACE. Plasma from four mice of 
each genotype (2 male and 2 female) was pooled, and the initial velocity determined using either the NH2-terminal specific substrate AcSDKP, 
the relatively COOH-terminal specific substrate HHL or angiotensin I. Results are expressed as percentage of the wild-type value. As expected, 
plasma from homozygous mutant mice contains much more activity against AcSDKP (89% of wild type) than HHL (6%). (D) The influence of 
chloride on the hydrolysis of HHL was determined. Plasma from wild-type or homozygous mutant mice was dialyzed against distilled water and 
various chloride concentrations were added to aliquots of the dialyzed plasma. ACE activity toward HHL was determined as before. Plasma 
from wild-type (+/+) mice shows a much greater activation by chloride than that from homozygous mutant (—/—) animals, consistent with the 
known chloride insensitivity of the amino terminus of ACE (5).
Blood pressure. To test whether restoration of circulating 
A C E would affect blood pressure, the systolic blood pressure 
of wild-type, heterozygous, and homozygous m utant ACE.2 
mice were measured using a computerized tail-cuff system 
(Fig. 5). Homozygous m utant mice had significantly lower sys­
tolic pressures (75 mmHg) than normal mice (110 mmHg). 
Heterozygous mice were no different from wild type (110 
mmHg). However, heterozygous females did have somewhat 
lower average blood pressures (95 mmHg). The reason for this 
is unknown. The low systolic blood pressures of the ACE.2 ho­
mozygous m utant mice are not significantly different to those 
seen in completely ACE-deficient mice, suggesting that circu­
lating A C E plays a relatively minor role in the control of blood 
pressure.
Renal structure and function. The kidneys from wild-type, 
heterozygous, and homozygous m utant mice were examined
histologically. The kidneys from homozygous m utant mice ex­
hibited vascular hypertrophy of small arteries and arterioles. 
The severity of this phenotype varied between normal vascular 
structure to marked vascular thickening. There was no appar­
ent correlation between the degree of vascular thickening and 
the blood pressure or the age at death of the individual ani­
mals (data not shown). No vascular thickening was present in 
heterozygous animals.
It has previously been reported that animals lacking all 
A C E have a marked medullary and papillary atrophy (17). 
This was carefully examined in the ACE.2 homozygous mu­
tant mice. Both by visual inspection of the kidney and by mi­
croscopic examination, 14 of 18 animals presented with renal 
medullary and papillary development similar to wild-type mice 
(Fig. 6 A ). One animal presented with unilateral calyceal dila­
tation, and three animals had calyceal dilatation similar to that
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Gender and Genotype
Figure 5. Blood pressure. The systolic blood pressures of male and 
female wild-type (+/+), heterozygous (+ /—), and homozygous mu­
tant (—/—) mice (n = 7-9 per group) were determined by a comput­
erized tail-cuff system. Each data point represents the mean of 4 d of 
measurements taken after a 7-d training period. The average for each 
group is represented by a broken bar. Homozygous mutant mice had 
blood pressures ~  40 mmHg lower than wild type (P < 0.01). No dif­
ferences were seen between genders in any genotype except het­
erozygotes, in which the females had a 15-mmHg lower blood pres­
sure than the males (P < 0.05).
seen in completely ACE-deficient mice. Present in approxi­
mately half the ACE.2 homozygous m utant mice is the focal 
expansion of Bowman’s space (Fig. 6 B). This pathology was 
seen in a small minority of glomeruli and was not associated 
with obvious distal nephron obstruction. Thus, whereas renal 
lesions were present in some of the ACE.2 homozygous m u­
tant mice, many lack the severe renal pathology observed in 
mice lacking production of all ACE.
Mice totally deficient in A C E cannot effectively concen­
trate urine, consistent with the medullary hypoplasia present 
in the kidneys of these animals (17). Urinary excretion was ex­
amined in the ACE.2 strain by 24-h urine collections accompa­
nied by water deprivation. Surprisingly, the homozygous m u­
tant mice of the ACE.2 strain had a urinary concentrating 
defect similar to that of mice totally deficient in the production 
of ACE. The ACE.2 homozygous mutants produced approxi­
mately twice the volume of urine as wild-type mice (1,473±133 
[—/ —] ^ l vs. 691±75 ^ l [+ /+ ]), Fig. 7 A). This urine was about 
half as concentrated as that of wild-type controls (1,166±87 
mosMol/kg [—/ —] vs. 1,963±178 mosMol/kg [+ /+ ], Fig. 7 B). 
Heterozygous mice were not different from norm al in this 
respect. Significantly, the concentrating defect was present in 
homozygous mutant mice with normal renal medullary and 
papillary structure (average volume 1,143±141 ^l, average os­
molality 1,140±112 mosMol/kg, n = 7 animals). Unlike mice 
that lack A CE, the urinary concentrating defect in the ACE.2 
homozygous m utant mice is not secondary to lack of a renal 
papilla. This finding provides evidence that the renin-angio- 
tensin system plays a major physiologic role in the urinary con­
centrating mechanism of mice.
Fertility. The ACE.2 homozygous males do not express the 
testis isoform of ACE. We therefore predicted that they would 
exhibit the same male fertility defect found in male mice that 
are totally deficient in ACE. These completely A C E deficient 
animals sire litters that are significantly smaller than wild-type 
controls despite producing mature sperm that are normal in 
number, morphology, and motility (17).
To test male fertility in the ACE.2 strain, male wild-type, 
heterozygous or homozygous m utant mice were mated to su­
perovulated wild-type C57BL/6 females. Homozygous mutant 
males sired significantly fewer litters (3 litters from 14 plugged 
females) than wild-type males (10 litters from 14 plugged fe­
males, x2 <  0.001). Furtherm ore, the litters from the homozy­
gous m utant males were significantly smaller than those from 
wild-type males (P <  0.001, Fig. 8). Thus, the ACE.2 strain ho­
mozygous m utant mice exhibit reduced male fertility similar to 
that seen in mice totally deficient in ACE. Histologic examina­
tion of the testis from ACE.2 homozygous m utant mice re­
vealed no morphologic abnormalities (data not shown). This is 
similar to the observation of a normal histology in the testis of 
males totally deficient in the production of ACE. Female fer­
tility appeared normal since both wild type and homozygous 
m utant females produced similar sized litters (average 4.3 
pups/litter for both genotypes) when mated to C57BL/6J 
males.
Discussion
Previously, our group characterized the ACE.1 strain of mice, 
which have a complete absence of both circulating and tissue 
A C E (17). These animals have low systolic blood pressures, 
abnormalities in renal structure, the inability to concentrate 
urine, and reduced male fertility. Heterozygotes of the ACE.1 
strain bear one unaltered A C E gene and contain ~  60% the 
wild-type levels of plasma and tissue A C E protein as deter­
mined by A C E activity measurement. Interestingly, these ani­
mals are phenotypically similar to wild-type mice dem onstrat­
ing that the effects of A C E deletion are not dominant.
The ACE.2 strain of mice described in this paper bear an 
unusual genetic lesion that results in the formation of a modi­
fied somatic A C E protein containing only the amino-terminal 
catalytic domain. This domain has been shown to be catalyti- 
cally active against the known physiological A C E substrates 
(5). Indeed, plasma from the ACE.2 homozygous m utant ani­
mals generates angiotensin II from angiotensin I at a rate that 
is 34% normal under zero order reaction conditions. The lev­
els are even higher (75%) under non-zero reaction conditions 
when substrate is limiting. However, because the modified 
A C E lacks the carboxy-terminal membrane anchor, this p ro­
tein is entirely secreted from cells. As a result, tissue A C E ac­
tivity is absent. The ACE.2 homozygous m utant mice are in 
many ways physiologically similar to the ACE.1 homozygous 
m utant mice completely lacking both circulating and tissue 
A C E (17). Both strains of mice have very low systolic blood 
pressures that are not statistically different from each other. 
Both are also unable to concentrate urine effectively. The
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Figure 6. Renal histology. (A) A  low power view (50X) of a kidney from a homozygous mutant mouse reveals that the renal medulla and papilla 
are intact. (B) Higher power view (250X) shows enlargement of Bowman’s spaces and vascular thickening of an arteriole.
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Figure 7. Urinalysis. Urine was collected from wild-type (+/+), het­
erozygous (+ /—), and homozygous mutant (—/—) mice (n = 11-13 
per group) for 24 h with water removed 6 h before the collection. (A ) 
Total urine volume was approximately twice as large in homozygous 
mutant mice as in either wild type or heterozygotes (P < 0.001). (B) 
The homozygous mutant mice produce urine that is half as concen­
trated as wild-type or heterozygous mice (P < 0.002).
ACE.1 and the ACE.2 strains of mice lack testis ACE, and 
therefore it is not surprising that both strains show an equiva­
lent defect in male fertility. A  significant difference between 
the two strains is the degree of renal pathology. ACE.1 ani­
mals present with medullary and papillary atrophy that is often 
apparent by 1 mo of age (unpublished observations). In  con­
trast, many of the ACE.2 homozygous m utant animals contain 
a preserved renal medulla and papilla even at 9 mo of age. This
Figure 8. Male fertility. 
The fertility of male 
wild-type (+/+) and 
homozygous mutant 
(—/—) mice was deter­
mined. Males were indi­
vidually housed and 
bred overnight to single 
superovulated females. 
The females were 
checked for copulatory 
plugs in the morning. 
The female mice were 
killed 2 wk after copula­
tion, and the number of 
pups were counted. Ho­
mozygous mutant 
males sire significantly 
fewer litters than wild 
type (x2 < 0.001), each of which contains significantly fewer pups per 
litter (P < 0.001).
difference is unlikely to be due to strain variation, since both 
lines of mice were generated in the same lab using the same ES 
cells and breeder strains. Thus, although the homozygous m u­
tant ACE.2 mice contain plasma A C E activity approaching 
that of ACE.1 heterozygotes, the ACE.2 mice exhibit much of 
the phenotype observed in the ACE.1 homozygous m utant 
animals lacking all ACE. This strongly suggests that circulat­
ing A C E is not sufficient for a functional renin-angiotensin 
system.
The abnormalities present in the homozygous mutant 
ACE.2 mice are similar to those described for mice completely 
lacking A C E and for mice that lack angiotensinogen, the p re­
cursor to angiotensin II (16, 17, 23, 24). This suggests that the 
ACE.2 homozygous m utant mice cannot generate sufficient 
angiotensin II despite significant plasma A C E activity; a find­
ing consistent with research indicating that the bulk of angio­
tensin II formation occurs in the tissues such as the lung (11). 
This study is also consistent with the concept of a local renin- 
angiotensin system. The components of the renin-angiotensin 
system exist in many organs and are postulated to regulate tis­
sue specific angiotensin II production (25). These local systems 
depend critically on the presence of tissue-bound A C E and are 
therefore nonfunctional in the ACE.2 homozygous mutants. 
A C E also plays a major role in the metabolism of bradykinin, 
and some of the phenotype may be due to increased levels of 
this vasodilator.
The difference in renal histology between the ACE.2 and 
ACE.1 underscores the role of A C E and the renin-angio- 
tensin system in kidney development. It has previously been 
reported that mice completely lacking A C E develop renal le­
sions that involve blunting of the renal papilla and associated 
dilatation of the renal calyces (17). These lesions are almost 
certainly due to lack of angiotensin II production since they 
also occur in mice that lack angiotensinogen and in rats treated 
neonatally with AT1 receptor antagonists (23, 24, 26). It is not 
clear whether the renal abnormalities are due directly to a re­
quirem ent for angiotensin II in normal renal development, or 
if they are secondary to the low blood pressure or increased 
urine flow present in these animals. Indeed, Brattleboro rats
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are unable to concentrate urine due to antidiuretic hormone 
deficiency and have an increased incidence of hydronephrotic 
lesions similar to those described for ACE-deficient mice (27). 
In contrast, many ACE.2 homozygous m utant mice have low 
blood pressure and defects in urinary concentration without 
marked medullary atrophy. This finding suggests that second­
ary effects are not solely responsible for this renal lesion. The 
ACE.2 homozygous m utant mice have a significant amount of 
circulating A CE activity, and this enzyme level may be suffi­
cient to rescue the medullary and papillary malformations but 
not the other physiological phenotypes in some instances.
The findings from the ACE.2 strain provide insight into the 
role of the renin-angiotensin system in urinary concentration 
mechanisms. Previous studies of urinary concentrating ability 
in A C E or angiotensinogen deficient mice were complicated 
by the renal abnormalities present in these animals. The present 
work with the A CE.2 strain  mice suggests tha t the ren in - 
angiotensin system plays a direct role in urinary concentration. 
The homozygous mutants produce an inappropriately dilute 
urine despite preservation of the renal papilla. These results 
are consistent with several studies that support a physiological 
role for the RA S in urine concentration. D irect injections of 
angiotensin II into the renal artery induce increases in urine 
osmolality (28), and mice that lack the AT1A receptor produce 
dilute urine despite a normal renal architecture (29). Several 
authors have suggested that the renin-angiotensin system is re­
quired to produce the low papillary blood flow necessary for 
maintenance of the normal renal concentration gradient (28, 
30). However, we cannot yet distinguish between this mecha­
nism and other possibilities, such as hemodynamically medi­
ated reductions in the delivery of solute to the loop of Henle. 
It is interesting to note that treatm ent of adult humans or ani­
mals with A C E inhibitors does not cause changes in urine os­
molality. This discrepancy is likely due to differences between 
the transient and incomplete blockade of tissue A CE achieved 
with an inhibitor and the perm anent and complete loss of tis­
sue A CE produced in our homozygous m utant mice.
The findings presented here further support a role for A CE 
in male fertility. Unlike the other physiologic abnormalities, 
this defect is not secondary to a lack of angiotensin II since an- 
giotensinogen deficient male mice have been reported as hav­
ing normal fertility (23). Although we strongly suspect that the 
testis isoform of A CE is im portant in male fertility, we cannot 
exclude the possibility that changes in blood pressure or renal 
function are responsible for the reduced fertility observed in 
the ACE.2 homozygous m utant males.
In summary, we report the construction and characteriza­
tion of mice containing a truncated form of somatic ACE. 
These animals have ^  34% the A CE activity in plasma but 
completely lack tissue ACE. The physiology of these animals 
is very similar to that of mice completely deficient in A C E and 
stands in sharp contrast to the normal physiology of heterozy­
gous ACE.1 animals containing reduced plasma A CE activity. 
These observations strongly support the concept that tissue- 
bound A CE activity is critical in the control of normal blood 
pressure and the ability of mice to concentrate urine effec­
tively.
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